Literature DB >> 21557378

The predictive validity of subjective adherence measures in patients with schizophrenia.

Martijn J Kikkert1, Maarten W J Koeter, Jack J M Dekker, Lorenzo Burti, Debbie Robson, Bernd Puschner, Aart H Schene.   

Abstract

Despite frequent use of subjective adherence measures in patients with schizophrenia as well as other chronic conditions, there are several reports that question the validity of these instruments. Three well known, representative subjective measures are the Medication Adherence Questionnaire (MAQ), the Drug Attitude Inventory (DAI), and the Compliance Rating Scale (CRS). In this study we explored the predictive validity of these instruments in a European sample of 119 stabilized outpatients with schizophrenia. Clinical outcome variables were relapse and admission to a psychiatric hospital during a follow-up period of 12 months. Results indicate that the predictive validity of all three measures was poor. The MAQ was the least problematic predictor for relapse (Nagelkerke R(2)  = 0.09), and time to relapse (R(2)  = 0.07) and had the best sensitivity for relapse (63.6%) as well as admission (87.5%). The MAQ and CRS were both moderate predictive for admission (Nagelkerke R(2)  = 0.21, and R(2)  = 0.29). We conclude that the validity of the instruments studied here is questionable and have limited clinical relevance. Given the feasibility and ease of most subjective instruments, researchers may be tempted to use them but should be aware of the serious drawbacks of these instruments.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21557378      PMCID: PMC6878246          DOI: 10.1002/mpr.335

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  45 in total

1.  Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

Authors:  Michael Eaddy; Amy Grogg; Julie Locklear
Journal:  Clin Ther       Date:  2005-02       Impact factor: 3.393

2.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

3.  Psychological predictors of insight and compliance in psychotic patients.

Authors:  R Kemp; A David
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

Review 4.  A critical evaluation of the methodology of the literature on medication compliance.

Authors:  M B Nichol; F Venturini; J C Sung
Journal:  Ann Pharmacother       Date:  1999-05       Impact factor: 3.154

5.  Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries.

Authors:  Mirella Ruggeri; Maarten Koeter; Aart Schene; Chiara Bonetto; Josè Luis Vàzquez-Barquero; Thomas Becker; Martin Knapp; Helle Charlotte Knudsen; Michele Tansella; Graham Thornicroft
Journal:  Schizophr Res       Date:  2005-06-01       Impact factor: 4.939

Review 6.  Determinants of medication compliance in schizophrenia: empirical and clinical findings.

Authors:  W S Fenton; C R Blyler; R K Heinssen
Journal:  Schizophr Bull       Date:  1997       Impact factor: 9.306

7.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.

Authors:  T P Hogan; A G Awad; R Eastwood
Journal:  Psychol Med       Date:  1983-02       Impact factor: 7.723

8.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Authors:  René S Kahn; W Wolfgang Fleischhacker; Han Boter; Michael Davidson; Yvonne Vergouwe; Ireneus P M Keet; Mihai D Gheorghe; Janusz K Rybakowski; Silvana Galderisi; Jan Libiger; Martina Hummer; Sonia Dollfus; Juan J López-Ibor; Luchezar G Hranov; Wolfgang Gaebel; Joseph Peuskens; Nils Lindefors; Anita Riecher-Rössler; Diederick E Grobbee
Journal:  Lancet       Date:  2008-03-29       Impact factor: 79.321

9.  Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Authors:  Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

10.  Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.

Authors:  Gunnar Morken; Jan H Widen; Rolf W Grawe
Journal:  BMC Psychiatry       Date:  2008-04-30       Impact factor: 3.630

View more
  4 in total

1.  Development of an Item Bank to Measure Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-08       Impact factor: 5.428

2.  Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Si Dun Weng; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Livia Jia Yi Oo; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-09       Impact factor: 5.428

3.  Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia.

Authors:  Nisha Warikoo; Subho Chakrabarti; Sandeep Grover
Journal:  Indian J Psychol Med       Date:  2014-01

4.  Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial.

Authors:  Stefanie N Rezansoff; Akm Moniruzzaman; Seena Fazel; Lawrence McCandless; Ric Procyshyn; Julian M Somers
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.